Clinical

Effect of frailty on HF readmissions


 

Title: Frailty is an independent risk factor for short-term mortality in older patients hospitalized with acute decompensated heart failure

Clinical Question: What is the effect of frailty on 30-day mortality in non–severely disabled older patients with acute decompensated heart failure?

Background: Existing research highlights the worsened short-term prognosis in older patients with acute decompensated heart failure, but has not examined if frailty is a specific independent risk factor for 30-day mortality in those without severe functional dependence.

Study Design: Retrospective secondary analysis of a prospective observational multicenter cohort study.

Setting: Three Spanish EDs.

Synopsis: In 465 patients age 65 and older with acute decompensated heart failure who did not have an ST-segment elevation myocardial infarction, severe functional dependence, or dementia, 36.3% were categorized as frail on a validated performance status scoring system. Frail patients had a higher 30-day mortality rate than did non-frail patients (13.0% versus 4.1% in non-frail patients). Frailty was independently associated with a 30-day mortality (hazard ratio = 2.5, P = .047).

The major limitations of this study are that the researchers did not report how many patients were discharged versus admitted from the ED and they did not stratify short-term mortality attributable to frailty by degree of medical comorbidity.

Bottom Line: Frailty is common in older patients with acute decompensated heart failure and is also an independent risk factor for short-term mortality.

Citation: Martin-Sanchez FJ, Rodriguez-Adrada E, Mueller C, et al. The effect of frailty on 30-day mortality risk in older patients with acute heart failure attended in the emergency department. Acad Em Med. 2017;24(3):298-307.

Dr. Barrett is assistant professor in the division of hospital medicine at the University of New Mexico.

Recommended Reading

Angiotensin II may improve vasopressors’ efficacy
The Hospitalist
HFrEF mortality halved when treatment matches guidelines
The Hospitalist
Rest dyspnea dims as acute heart failure treatment target
The Hospitalist
FDA approves betrixaban for VTE prophylaxis
The Hospitalist
Amplatzer devices outperform oral anticoagulation in atrial fib
The Hospitalist
Idarucizumab reversed dabigatran completely and rapidly in study
The Hospitalist
Plasma biomarker distinguishes ARDS, acute heart failure
The Hospitalist
What is the best approach for managing CIED infections?
The Hospitalist
High Value Care curriculum reduced echocardiogram ordering
The Hospitalist
Study: No increased mortality with ACA-prompted readmission declines
The Hospitalist
   Comments ()